龙8娱乐

当前位置: 首页 > 药学版 > 药品研究 > 药理药效学 > 正文
编号:10566761
Endothelin Antagonism with Bosentan: Current Status and Future Perspectives
http://www.100md.com
     Endothelin receptor antagonist have been proposed for the treatment of a variety of disorders in which the endothelins may act as pathogenic mediators, such as hypertension,congestive heart failure, and cerebral vasospasm. Bosentan is a nonpeptide competitiver:%t), 百拇医药

    antagonist, which can be a good tool for studying the endothelin system. It is specific forr:%t), 百拇医药

    the endothelin system and blocks the actions of endothelin at both mammalian receptorsr:%t), 百拇医药

    (A and B). Bosentan has recently moved into Phase III clinical trial. This review will attempt to overview the experimental and clinical effects of bosentan.
龙8娱乐qy8千亿国际欢迎您qy8千亿国际亚虎娱乐老虎机
亚虎娱乐老虎机龙8娱乐老虎机梦之城娱乐梦之城娱乐
亚虎娱乐老虎机qy8千亿国际欢迎您qy8千亿国际龙8娱乐官网
龙8娱乐龙8娱乐城开户送8 88龙8娱乐老虎机亚虎娱乐老虎机
亚虎娱乐老虎机龙8娱乐老虎机梦之城娱乐梦之城娱乐